Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO + hetrombopag for radiochemotherapy-induced thrombocytopenia in nasopharyngeal carcinoma
ChiCTR2400081992Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2024
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant human thrombopoietin and hetrombopag in Thrombocytopenia and nasopharyngeal carcinoma (NPC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Proportion of subjects with platelet count restored to ≥75×10^9/L after 1 week of recombinant human thrombopoietin + hetrombopag. Started Mar 2024; status: recruiting.
02
Drugs
recombinant human thrombopoietinhetrombopag
03
Conditions
Thrombocytopenianasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2400081992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081992.